MediciNova Capital Surpluse from 2010 to 2025

MNOV Stock  USD 1.47  0.02  1.34%   
MediciNova Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 427.3 M in 2025. During the period from 2010 to 2025, MediciNova Capital Surpluse regression line of quarterly data had mean square error of 927.5 T and geometric mean of  395,058,707. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
477.8 M
Current Value
478.2 M
Quarterly Volatility
64.1 M
 
Yuan Drop
 
Covid
Check MediciNova financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MediciNova's main balance sheet or income statement drivers, such as Interest Expense of 679.1 K, Other Operating Expenses of 14.5 M or Research Development of 7.8 M, as well as many indicators such as Price To Sales Ratio of 107, Dividend Yield of 0.0 or PTB Ratio of 1.63. MediciNova financial statements analysis is a perfect complement when working with MediciNova Valuation or Volatility modules.
  
Check out the analysis of MediciNova Correlation against competitors.
For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.

Latest MediciNova's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of MediciNova over the last few years. It is MediciNova's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MediciNova's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

MediciNova Capital Surpluse Regression Statistics

Arithmetic Mean401,543,413
Geometric Mean395,058,707
Coefficient Of Variation18.66
Mean Deviation65,403,552
Median427,253,745
Standard Deviation74,938,584
Sample Variance5615.8T
Range239.1M
R-Value0.92
Mean Square Error927.5T
R-Squared0.85
Slope14,476,303
Total Sum of Squares84236.9T

MediciNova Capital Surpluse History

2025427.3 M
2024549.1 M
2022477.4 M
2021476.8 M
2020454.3 M
2019444 M
2018429.3 M

About MediciNova Financial Statements

MediciNova investors use historical fundamental indicators, such as MediciNova's Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MediciNova. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse549.1 M427.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.